Combination therapy for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of drugs for people with advanced colorectal cancer that has not responded to standard treatments. It may help control the cancer and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with metastatic colorectal cancer (cancer that has spread).
- You are able to care for yourself (ECOG score 0-2).
- You have had at least one evaluation of how well the treatment worked.
- You are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This study looks at a combination of a drug called chidamide with immunotherapy and anti-angiogenic therapy (which blocks blood supply to tumors) for advanced colorectal cancer that is MSS-type. The goal is to see how effective this combination is in real-world settings, meaning it may offer a new option for people whose cancer has not responded to other treatments.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
This trial tests a combination of four drugs for people with advanced colorectal cancer who have already tried at least two other treatments. The goal is to see if this new mix can help shrink tumors or slow the cancer's growth.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.